CAR T-Cells That Fight Ovarian and Prostate Cancer by Targeting LHR
This patent describes a new type of CAR T-cell therapy designed to fight ovarian and prostate cancers by specifically targeting the Luteinizing Hormone Receptor (LHR) protein found on cancer cells.
Patent Number
US 20250129171
Status
Active
Filing Date
May 20, 2024
Grant Date
—
Expiration
May 20, 2044
Claims
22
Assignee
University of Southern California
Inventors
Alan L. Epstein, Peisheng Hu, Jacek K. Pinski
Citations
0 forward · 0 backward
What it covers
This patent describes a Chimeric Antigen Receptor (CAR) that specifically targets the Luteinizing Hormone Receptor (LHR) protein. This CAR is made up of several parts: an "antigen binding domain" from an anti-LHR antibody (using specific heavy and light chain variable regions, like SEQ ID NO.: 3 and 7), a "hinge domain," a "transmembrane domain," a "costimulatory signaling region," and a "CD3 zeta signaling domain" (Claim 1). These CARs are then put into immune cells, typically T-cells or Natural Killer (NK) cells (Claim 8), making them into a targeted therapy. When these modified T-cells or NK cells encounter cancer cells that have LHR on their surface, they are designed to attack and inhibit the growth of those cancer cells (Claim 11, 13). For example, a patient with prostate cancer that expresses LHR could receive these modified T-cells to specifically target and destroy their tumor cells.
What it doesn't cover
- —CAR T-cell therapies that target cancer proteins other than the Luteinizing Hormone Receptor (LHR).
- —CAR T-cells that do not include all the specified components, such as a hinge domain, transmembrane domain, costimulatory signaling region, and CD3 zeta signaling domain.
- —CAR T-cells where the antigen binding domain does not use the specific antibody sequences (SEQ ID NO.: 3 and 7) or sequences with at least 90% identity to them.
- —Methods of treating cancers that do not express or overexpress the LHR protein.
- —Traditional chemotherapy, radiation therapy, or surgical methods for cancer treatment.
The clever bit
The clever bit is identifying and validating the Luteinizing Hormone Receptor (LHR) as a specific and effective target for CAR T-cell therapy in solid tumors like ovarian and prostate cancer. This patent provides the precise genetic blueprints (specific antibody sequences) needed to engineer T-cells to recognize and attack LHR-expressing cancer cells.
Why it matters
Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of certain blood cancers, but treating solid tumors like ovarian and prostate cancer remains a significant challenge. This patent focuses on a novel approach to target LHR, a protein found on some solid tumor cells, potentially opening new avenues for treatment. By providing specific antibody sequences, it lays a foundation for developing precise immunotherapies against these hard-to-treat cancers.
Real-world examples
- 1.Kymriah (Novartis, a CAR T-cell therapy for blood cancers)
- 2.Yescarta (Gilead, a CAR T-cell therapy for blood cancers)
- 3.Prostate cancer treatments
- 4.Ovarian cancer treatments
- 5.Antibody-drug conjugates (another form of targeted therapy)
Generated by PatentBrief · Not legal advice · patentbrief.org
US 20250129171 · 2026